TIBIO – Azienda ticinese selezionata tra gli attori chiave nel mercato mondiale dei prodotti chimici basati sulle biotecnologie 13 February 2023
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs 6 February 2023
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets 24 January 2023
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer 17 January 2023
Linkedin